Yuan Shao

Dr. Yuan Shao


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2015 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
YSYuan Shao
Yuan Shao
DWDa-Wei Wang
Da-Wei Wang
GLGuo-Liang Lu
Guo-Liang Lu
ZSZhou-Jun Shen
Zhou-Jun Shen

8 September 2018 in Inflammation
Verified
Journal Article
Closed access
PDF file
BLBo-Ke Liu
Bo-Ke Liu
XJXing-Wei Jin
Xing-Wei Jin
HLHao-Zhong Lu
Hao-Zhong Lu
XZXiang Zhang
Xiang Zhang
ZZZhong-Hua Zhao
Zhong-Hua Zhao
YSYuan Shao
Yuan Shao

1 November 2021 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
XJXing-Wei Jin
Xing-Wei Jin
QWQi-Zhang Wang
Qi-Zhang Wang
YZYang Zhao
Yang Zhao
BLBo-Ke Liu
Bo-Ke Liu
XZXiang Zhang
Xiang Zhang
YSYuan Shao
Yuan Shao
An experimental model of the epithelial to mesenchymal transition and pro-fibrogenesis in urothelial cells related to bladder pain syndrome/interstitial cystitis Xing-Wei Jin, Qi-Zhang Wang, Yang Zhao, Bo-Ke Liu, Xiang Zhang, Xian-Jin Wang, Guo-Liang Lu, Jun-Wei Pan, Yuan Shao

23 February 2012 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
YSYuan Shao
Yuan Shao
GLGuo-Liang Lu
Guo-Liang Lu
ZSZhou-Jun Shen
Zhou-Jun Shen
HHHong-Chao He
Hong-Chao He

23 February 2017 in Inflammation
Verified
Journal Article
Closed access
PDF file
XJXing-Wei Jin
Xing-Wei Jin
BLBo-Ke Liu
Bo-Ke Liu
XZXiang Zhang
Xiang Zhang
ZZZhong-Hua Zhao
Zhong-Hua Zhao
YSYuan Shao
Yuan Shao

20 March 2023 in Chinese Medical Journal
Verified
Journal Article
Open access
XJXingwei Jin
Xingwei Jin
QWQizhang Wang
Qizhang Wang
FLFangxiu Luo
Fangxiu Luo
JPJunwei Pan
Junwei Pan
TLTingwei Lu
Tingwei Lu
YSYuan Shao
Yuan Shao
Background: Heterogeneity of tumor cells and the tumor microenvironment (TME) is significantly associated with clinical outcomes and treatment responses in patients with urothelial carcinoma (UC). Comprehensive profiling of the cellular diversity and interactions between malignant cells and TME may clarify the mechanisms underlying UC progression and guide the development of novel therapies. This study aimed to extend our understanding of intra-tumoral heterogeneity and the immunosuppressive TME in UC and provide basic support for the development of novel UC therapies. Methods: Seven patients with UC were included who underwent curative surgery at our hospital between July 2020 and October 2020. We performed single-cell RNA sequencing (scRNA-seq) analysis in seven tumors with six matched adjacent normal tissues and integrated the results with two public scRNA-seq datasets. The functional properties and intercellular interactions between single cells were characterized, and the results were validated using multiplex immunofluorescence staining, flow cytometry, and bulk transcriptomic datasets. All statistical analyses were performed using the R package with two-sided tests. Wilcoxon-rank test, log-rank test, one-way analysis of variance test, and Pearson correlation analysis were used properly. Results: Unsupervised t-distributed stochastic neighbor embedding clustering analysis identified ten main cellular subclusters in urothelial tissues. Of them, seven urothelial subtypes were noted, and malignant urothelial cells were characterized with enhanced cellular proliferation and reduced immunogenicity. CD8+ T cell subclusters exhibited enhanced cellular cytotoxicity activities along with increased exhaustion signature in UC tissues, and the recruitment of CD4+ T regulatory cells was also increased in tumor tissues. Regarding myeloid cells, coordinated reprogramming of infiltrated neutrophils, M2-type polarized macrophages, and LAMP3+ dendritic cells contribute to immunosuppressive TME in UC tissues. Tumor tissues demonstrated enhanced angiogenesis mediated by KDR+ endothelial cells and RGS5+/ACTA2+ pericytes. Through deconvolution analysis, we identified multiple cellular subtypes may influence the programmed death-ligand 1 (PD-L1) immunotherapy response in patients with UC. Conclusion: Our scRNA-seq analysis clarified intra-tumoral heterogeneity and delineated the pro-tumoral and immunosuppressive microenvironment in UC tissues, which may provide novel therapeutic targets.